NASD · Healthcare · Biotechnology · USA
X4 Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapies for rare hematology diseases. Its primary asset is mavorixafor, an orally delivered small molecule antagonist of chemokine receptor CXCR4. The company has one approved product, XOLREMDI, which received FDA accelerated approval for treating WHIM syndrome, and is conducting a pivotal clinical trial in chronic neutropenia.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the X4 Pharmaceuticals Inc stock.
Overvalued: intrinsic value $1.54 per share, market price $3.09, margin of safety -100.5% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $1.54; the price of $3.09 is 100% above that value.
12 more funds hold it; the full list is part of the paid plan.
56 more in this industry show a wider margin of safety.
XFOR is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.54; the price of $3.09 is 100% above that value.
$1.54 per share (as of the 2026-11-17 close), against a market price of $3.09. That is a margin of safety of -100.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.